Literature DB >> 6370708

Comparison of the ocular hypotensive efficacy of eicosanoids and related compounds.

L Z Bito.   

Abstract

It has recently been shown that prostaglandin (PG)E2 or F2 alpha reduces the intraocular pressure (IOP) of cats and primates when applied topically to the eye in very small doses, and that reduced IOP can be maintained in these species as long as the topical application of one of these PGs is repeated daily or twice daily. In the present study the ocular hypotensive efficacy and some of the ocular side-effects of 15 eicosanoids and related compounds, especially derivatives of PGF2 alpha, were compared and were also compared to some clinically used ocular hypotensive agents. Derivatives of PGF2 alpha were found that had short-term and long-term ocular hypotensive potencies some 10- to 50-fold greater than PGF2 alpha itself.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6370708     DOI: 10.1016/0014-4835(84)90102-7

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  10 in total

Review 1.  Prodrugs for the improvement of drug absorption via different routes of administration.

Authors:  L P Balant; E Doelker; P Buri
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

2.  Ocular neovascularization. Experimental animal model and studies on angiogenic factor(s).

Authors:  S S Hayreh; G F Lata
Journal:  Int Ophthalmol       Date:  1986-05       Impact factor: 2.031

3.  Prostaglandin F2 alpha-isopropylester eye drops: effect on intraocular pressure in open-angle glaucoma.

Authors:  J Villumsen; A Alm; M Söderström
Journal:  Br J Ophthalmol       Date:  1989-12       Impact factor: 4.638

4.  Prostaglandin F2 alpha-isopropylester eye drops: effects in normal human eyes.

Authors:  J Villumsen; A Alm
Journal:  Br J Ophthalmol       Date:  1989-06       Impact factor: 4.638

5.  The EP2 receptor is the predominant prostanoid receptor in the human ciliary muscle.

Authors:  T Matsuo; M S Cynader
Journal:  Br J Ophthalmol       Date:  1993-02       Impact factor: 4.638

Review 6.  Pharmacological advances in the treatment of glaucoma.

Authors:  J B Serle
Journal:  Drugs Aging       Date:  1994-09       Impact factor: 3.923

7.  Synthesis, physicochemical properties, and cytotoxicity of a series of 5'-ester prodrugs of 5-iodo-2'-deoxyuridine.

Authors:  M M Narurkar; A K Mitra
Journal:  Pharm Res       Date:  1988-11       Impact factor: 4.200

8.  Studies on a novel series of acyl ester prodrugs of prostaglandin F2 alpha.

Authors:  A Cheng-Bennett; M F Chan; G Chen; T Gac; M E Garst; C Gluchowski; L J Kaplan; C E Protzman; M B Roof; G Sachs
Journal:  Br J Ophthalmol       Date:  1994-07       Impact factor: 4.638

9.  Intraocular pressure reduction with once-a-day application of a new prostaglandin eye drop: a pilot placebo-controlled study in 12 patients.

Authors:  Ciro Caruso; Luigi Pacente; Pasquale Troiano; Carmine Ostacolo; Luca D'Andrea; Silvia Bartollino; Ciro Costagliola
Journal:  Int Ophthalmol       Date:  2019-12-03       Impact factor: 2.031

10.  Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations.

Authors:  Masamichi Fukuda; Shinsuke Shibata; Naoko Shibata; Kenta Hagihara; Hiromoto Yaguchi; Hiromi Osada; Nobuo Takahashi; Eri Kubo; Hiroshi Sasaki
Journal:  Clin Ophthalmol       Date:  2013-03-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.